Skip to main content

Agilent Technologies Value Stock - Dividend - Research Selection

Agilent Technologies

ISIN: US00846U1016, WKN: 929138

Market price date: 19.05.2022
Market price: 122,40 USD

Agilent Technologies Fundamental data and company key figures of the share

Annual reports in USD
Key figures 24-11-2021
Cash flow
Net operating cash flow 1.485.000.000
Capital Expenditures -188.000.000
Free cash flow 1.296.999.936
Balance sheet
Total Equity 5.389.000.000
Liabilities & Shareholders equity 10.705.000.000
Income statement
Net income
Eps (diluted) 3,954
Diluted shares outstanding 306.000.000
Net sales/revenue 6.319.000.000

Fundamental ratios calculated on: 19-05-2022

Key figures 19-05-2022
Cash flow
P/C 25,22
P/FC 28,88
Balance sheet
Income statement
Div. Yield0,62%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization37.454.401.536,00 USD
CountryUnited States
IndicesMSCI World Index,S&P 500
SectorsLife Sciences Tools & Services
Raw Data SourceUS GAAP in Millionen USD
Stock Split2014-11-04,1398.0000/1000.0000; 2014-11-03,1398.0000/1000.0000; 2014-09-29,1.000000/10.000000; 2013-07-31,1.000000/10.000000

Description of the company

Agilent Technologies, Inc. (Agilent) is a measurement company providing bio-analytical and electronic measurement solutions to the communications, electronics, life sciences and chemical analysis industries. During the fiscal year ended October 31, 2011 (fiscal 2011), it had three business segments: electronic measurement business, chemical analysis business and life sciences business. Its electronic measurement business addresses the communications, electronics and other industries. Agilent's chemical analysis business focuses on the petrochemical, environmental, forensics and food safety industries. Its life sciences business focuses on the pharmaceutical, biotechnology, academic and Government, bio-agriculture and food safety industries. In addition to its three businesses, it conducts research through Agilent Technologies Laboratories (Agilent Labs). In June 2012, the Company acquired cancer diagnostics company, Dako. In August 2012, the Company acquired Aurora SFC Systems, Inc.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,


Agilent Technologies : Statement of Changes in Beneficial Ownership (Form 4)

Ownership Submission FORM 4 Check this box if no longer... | May 20, 2022

Agilent Announces Cash Dividend of 21 Cents per Share

SANTA CLARA, Calif., May 18, 2022--Agilent Technologies Inc. (NYSE: A) today announced a quarterly dividend of 21 cents per share of common stock will be paid on July 27, 2022, to all shareholders of record as of the close of business on July 5, 2022.

Agilent Technologies (A) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Agilent (A) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

SEC filings reveal massive selling in media names, including Disney and Comcast

Leslie Picker joins the 'Halftime Report' to discuss what to expect from the SEC 13-F filings.

Citi opens 'positive catalyst watch' on Agilent into earnings

Citi analyst Patrick Donn... A

Agilent Companion Diagnostic Expands CE-IVD Mark in Europe to Include Cervical Cancer

SANTA CLARA, Calif., May 10, 2022--Agilent Technologies Inc. (NYSE: A) today announced that its PD-L1 IHC 22C3 pharmDx, Code SK006, is now EU CE-IVD–marked for use in cervical cancer. PD-L1 IHC 22C3 pharmDx can be used as an aid in identifying cervical cancer patients for whom treatment with KEYTRUDA® (pembrolizumab) may be appropriate.1 KEYTRUDA is an anti-PD-1 therapy developed by Merck (known as MSD outside the U.S. and Canada). In Europe, KEYTRUDA, in combination with chemotherapy with or wi

Agilent reports expanded CE-IVD mark in Europe for companion diagnostic

Agilent Technologies (A) ... A, MRK

Cable companies to offer effectively free internet to low-income homes

The news means that tens of millions of households could receive high-speed internet at no cost, according to the White House.

Ken Fisher is Selling These 10 Stocks in 2022

In this article, we will discuss some stocks sold by Ken Fisher in the first quarter. You can skip this part and go to read Ken Fisher is Selling These 5 Stocks in 2022. Ken Fisher is one of the most followed finance experts in the world. Fisher, whose worth stands at $5 billion, is […]

Agilent Technologies Inc. stock falls Friday, underperforms market

Shares of Agilent Technologies Inc. shed 0.88% to $121.08 Friday, on what proved to be an all-around rough trading session for the stock market, with the S&P...